S-1/A: Autonomix Medical Seeks $9 Million in Public Offering to Advance Nerve-Sensing Technology

Autonomix Medical is launching a firm commitment public offering to raise up to $9 million for clinical trials and development of its nerve-sensing and treatment technology.

Summary

• Autonomix Medical, a medical device company, is offering up to 698,812 common stock units, each including one share of common stock and one Series A warrant, with an assumed offering price of $14.31 per unit.
• The company is also offering pre-funded warrant units (PFW Units) to purchasers who would otherwise exceed beneficial ownership limits.
• Each PFW Unit consists of one pre-funded warrant and one Series A warrant.
• The company intends to use the net proceeds of approximately $9.0 million to fund clinical trials, research and development, intellectual property development, and working capital.
• Autonomix Medical is developing a catheter-based microchip-enabled sensing array for detecting and treating nervous system disorders, initially focusing on pancreatic cancer pain.
• The company's technology aims to improve the precision and safety of nerve ablation procedures.
• Autonomix Medical has an accumulated deficit of $44.5 million as of September 30, 2024, and its independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company completed a 1-for-20 reverse stock split on October 24, 2024, to regain compliance with Nasdaq listing rules.
• Preliminary results from a proof-of-concept human clinical trial showed positive outcomes in pain reduction for patients treated with femoral access.

Sentiment

Score: 5

Explanation: The document presents both positive clinical trial results and significant financial risks, resulting in a neutral sentiment.

Positives

• Preliminary clinical trial results indicate significant pain reduction and elimination of opioid use in responding patients.
• The company's technology has demonstrated superior sensitivity compared to existing devices in animal studies.
• The company is targeting a significant unmet need in pancreatic cancer pain management.
• The company has a broad intellectual property portfolio with 87 issued patents and 42 pending patent applications.
• The company has a license agreement with RF Innovations, Inc. for ablation technology.

Negatives

• The company has a significant accumulated deficit of $44.5 million as of September 30, 2024.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company is a development stage company with no approved products and no history of generating revenue.
• The company intends to utilize a single manufacturer for its lead product candidate.
• The company has no experience in assembling and testing its products on a commercial scale.
• The company may be required to issue up to 271,846 shares of common stock in connection with the reverse stock split.

Risks

• The company may be required to issue up to 271,846 shares of common stock in connection with the reverse stock split.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company has no approved products and may not generate revenue or become profitable.
• The company intends to utilize a single manufacturer for its lead product candidate.
• The company is a developmental stage company with no history of generating revenue.
• The company has no experience in assembling and testing its products and may encounter problems or delays.
• Rapidly changing technology in life sciences could make the products the company is developing obsolete.
• The company may fail to meet the Sarbanes-Oxley regulations and may lack the financial controls and safeguards required of public companies.
• There is no guarantee that the FDA will grant 510(k) or de novo clearance or a premarket approval application (PMA) of the company's future products.
• The results of the company's future clinical trials may not support its product candidate claims or may result in the discovery of adverse side effects.
• The company plans to conduct its initial Proof of Concept trial outside the United States and there is no assurance that the FDA will accept this data.
• The company's clinical studies could be delayed or otherwise adversely affected by many factors, including difficulties in enrolling patients.
• If the company is unable to establish good relationships with physicians, its business could be negatively affected.
• The company's business and operations would suffer in the event of third-party computer system failures, cyber-attacks on third-party systems or deficiency in its cyber security.
• The company may incur substantial costs as a result of proceedings relating to patent and other intellectual property rights.
• The company has broad discretion in how it uses the proceeds of this offering and may not use these proceeds effectively.
• The company will require substantial funding, which may not be available to it on acceptable terms, or at all.
• Purchasers in this offering will experience immediate and substantial dilution in net tangible book value.
• The company completed a reverse stock split on October 24, 2024 in an effort to regain compliance with Nasdaq listing rules and the effect is uncertain.
• Concentration of ownership of the company's common stock among its existing executive officers and directors may prevent new investors from influencing significant corporate decisions.
• The requirements of being a public company may strain the company's resources, divert managements attention and affect its ability to attract and retain qualified board members.

Future Outlook

The company plans to continue clinical development and commercialization activities, requiring substantial additional capital. The company estimates that it will require additional financing of approximately $40 million to fund its operations through initial commercial launch. The timing and costs of clinical trials are difficult to predict and trial plans may change in response to evolving circumstances and as such the foregoing estimates may prove to be inaccurate.

Management Comments

• The company believes its technology constitutes a platform with the potential to address dozens of indications in a range of areas including chronic pain management from all causes, hypertension, cardiovascular disease and a wide range of other nerve-related disorders.
• The company believes, if it can recreate these results in clinical trials, this will enable a method of transvascular targeting, treating, and confirming treatment of diseases involving the nervous system throughout the body that is not currently available and may be capable of filling a wide range of unmet medical needs.

Industry Context

The electrophysiology market is served by large players like Medtronic and Boston Scientific. The company's technology aims to expand electrophysiology beyond cardiology to include the peripheral nervous system. The company believes enabling targeted transvascular treatment of pain will enable it to access the $78 billion pain management market, as cited in the Mordor Intelligence Pain Management Market Industry Report. Additionally, if the company is able to facilitate a safer, more targeted method for renal denervation it may be able to access the $25 billion hypertension market, as indicated by Polaris Market Research.

Comparison to Industry Standards

• The Autonomix device has metrics of <1uV for signal detection levels and roughly 0.02mm by 0.03mm for the electrode dimensions.
• For the BSC Orion, the nearest device on the market, the metrics are 10uV for signal detection levels, and roughly 0.4mm by 0.5mm for the electrode dimensions.
• The differences in these metrics result in a calculation of 3,000 times greater sensitivity for the Autonomix device.

Management Changes

Related Party Transactions

• The company utilizes a consulting firm that is owned by the Companys former Chief Financial Officer to provide accounting and financial reporting services and pays certain expenses on behalf of the Company.
• As of March 31, 2024, members of the Companys management/Board and an immediate family member of the Companys management (related party), collectively purchased $0.5 million ($0.4 million and $0.1 million, respectively) of the Bridge Offering.
• On December 21, 2021, the Company entered into a perpetual, worldwide, exclusive license agreement (the License or License Agreement) with a company controlled by a significant stockholder of the Company (the Licensee).

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the public offering and the reverse stock split.
• Patients with pancreatic cancer may benefit from the development of a more effective pain management solution.
• Employees may be impacted by the company's ability to secure funding and continue operations.

Next Steps

• Continue clinical development of the nerve-sensing technology.
• Seek regulatory clearance for the technology.
• Commercialize the technology for pancreatic cancer pain management and other indications.

Key Dates

Keywords

Autonomix Medical, public offering, common stock, warrants, nerve sensing, pancreatic cancer, clinical trials, ablation, medical device, femoral access, reverse stock split, FDA, AMIX